Dr. Sundas Khan
Overview
Sundas Khan is a Hematologist and an Oncologist in Lancaster, Pennsylvania. Dr. Khan is rated as an Experienced provider by MediFind in the treatment of Liver Cancer. Her top areas of expertise are DICER1 Syndrome, HER2 Negative Breast Cancer, BRCA Positive Breast Cancer, and Familial Colorectal Cancer. Dr. Khan is currently accepting new patients.
Her clinical research consists of co-authoring 1 peer reviewed article. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- MEDICARE PDP
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- OTHER MEDICARE PART D
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE SNP
- OTHER MEDICARE PART D
- HMO
- POS
- PPO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE SNP
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
2102 Harrisburg Pike, Lancaster, PA 17601
Additional Areas of Focus
Dr. Khan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Johns Hopkins University
Mark Yarchoan is an Oncologist in Baltimore, Maryland. Dr. Yarchoan is rated as a Distinguished provider by MediFind in the treatment of Liver Cancer. His top areas of expertise are Fibrolamellar Carcinoma, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Pancreatic Cancer, and Hepatectomy. Dr. Yarchoan is currently accepting new patients.
Consultants In Medical Oncology And Hematology PC
John Sprandio is a Hematologist Oncology specialist and a Hematologist in Broomall, Pennsylvania. Dr. Sprandio is rated as a Distinguished provider by MediFind in the treatment of Liver Cancer. His top areas of expertise are Hairy Cell Leukemia (HCL), Liver Cancer, Familial Colorectal Cancer, and Paget Disease of the Breast.
The Milton S Hershey Medical Center Physicians Group
Nelson Yee is a Hematologist Oncology specialist and a Hematologist in Hershey, Pennsylvania. Dr. Yee is rated as a Distinguished provider by MediFind in the treatment of Liver Cancer. His top areas of expertise are Pancreatic Cancer, Cholangiocarcinoma (Bile Duct Cancer), Neuroendocrine Tumor, Familial Pancreatic Cancer, and Bone Marrow Aspiration.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- DICER1 SyndromeDr. Khan isAdvanced. Learn about DICER1 Syndrome.
- Experienced
- Atypical Hemolytic Uremic Syndrome (aHUS)
- BRCA Positive Breast CancerDr. Khan isExperienced. Learn about BRCA Positive Breast Cancer.
- D-Plus Hemolytic Uremic SyndromeDr. Khan isExperienced. Learn about D-Plus Hemolytic Uremic Syndrome.
- Familial Colorectal CancerDr. Khan isExperienced. Learn about Familial Colorectal Cancer.
- Hemolytic-Uremic SyndromeDr. Khan isExperienced. Learn about Hemolytic-Uremic Syndrome.
- HER2 Negative Breast CancerDr. Khan isExperienced. Learn about HER2 Negative Breast Cancer.